Advances include the use of meclofenamic acid 2, also known as the ethyl ester derivative of meclofenamic acid, which acts as a selective FTO inhibitor by competing for FTO binding sites, suppressing tumour progression in glioblastoma27. Here, FTO is linked to neoplasm.